Mitamura T, Kitaoka M, Watanabe M, Okuba K, Tenjin S, Yamada S, et al. Study on Japanese encephalitis virus. Animal experiments and mosquito transmission experiments. Kansai Iji. 1936;1:260–70.

Google Scholar 

• Burke DS, Leake CJ. Japanese encephalitis. In: Monath TP, editor. The arboviruses: epidemiology and ecology. 3rd ed. Boca Raton: CRC Pres; 1988. p. 63–92. An excellent review on the epidemiology of JEV.

Google Scholar 

Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89:766–4E. https://doi.org/10.2471/BLT.10.085233.

Article  PubMed  PubMed Central  Google Scholar 

Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. In: Mackenzie JS, Barrett ADT, Deubel V, editors. Japanese encephalitis and West Nile viruses. Current Topics in Microbiology and Immunology, vol. 267. Berlin: Springer; 2002.

Google Scholar 

Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg. 2001;65(3):242–51.

CAS  Article  Google Scholar 

Takegami T, Miyamoto H, Nakamura H, Yasui K. Biological activities of the structural proteins of Japanese encephalitis virus. Acta Virol. 1982;26(5):312–20.

CAS  PubMed  Google Scholar 

Oya A. Immunity and prediction of epidemic in Japanese encephalitis. NAIKA. 1966;17:905–9.

CAS  PubMed  Google Scholar 

•• Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319(10):608–14. https://doi.org/10.1056/nejm198809083191004 One of only two placebo-controlled, blinded, randomized trial of a JEV vaccine in a large cohort of children.

CAS  Article  PubMed  Google Scholar 

Muangchana C, Henprasertthae N, Nurach K, Theppang K, Yoocharoen P, Varinsathien P, et al. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case–control study. Vaccine. 2012;30(2):361–7. https://doi.org/10.1016/j.vaccine.2011.10.083.

CAS  Article  PubMed  Google Scholar 

Okada K, Iwasa T, Namazue J, Akechi M, Ueda S. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK®V) in children. Vaccine. 2012;30(41):5967–72. https://doi.org/10.1016/j.vaccine.2012.07.034.

CAS  Article  PubMed  Google Scholar 

Yun KW, Lee HJ, Kang JH, Eun BW, Kim Y-J, Kim K-H, et al. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial. BMC Infect Dis. 2015;15(1):7. https://doi.org/10.1186/s12879-014-0744-4.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yu Y Development of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and its charcteristics. in “Encephalitis” Ch 11; IntechOpen, publishers. 2013. https://doi.org/10.5772/52980. -A comprehensive “go to” review on the travails of developing SA-14-14-2.

•• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73(4):3095–101 First report proving that the attenuated phenotype of SA14-14-2 was determined by the mutations in the envelope protein and construction of the most successful vaccine built on the ChimeiVax platform.

CAS  Article  Google Scholar 

Arroyo J, Guirakhoo F, Fenner S, Zhang Z-X, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001;75(2):934–42. https://doi.org/10.1128/jvi.75.2.934-942.2001.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Gromowski GD, Firestone C-Y, Whitehead SS. Genetic determinants of Japanese encephalitis virus vaccine strain SA14-14-2 that govern attenuation of virulence in mice. J Virol. 2015;89(12):6328–37. https://doi.org/10.1128/jvi.00219-15.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bonaldo MC, Caufour PS, Freire MS, Galler R. The yellow fever 17D vaccine virus as a vector for the expression of foreign proteins: development of new live flavivirus vaccines. Mem Inst Oswaldo Cruz. 2000;95:215–23.

CAS  Article  Google Scholar 

Galler R, Freire MS, Jabor AV, Mann GF. The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector. Braz J Med Biol Res. 1997;30:157–68.

CAS  Article  Google Scholar 

Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999;17(15–16):1869–82. https://doi.org/10.1016/s0264-410x(98)00487-3.

CAS  Article  PubMed  Google Scholar 

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3):632–49. https://doi.org/10.1016/j.vaccine.2009.09.098.

CAS  Article  PubMed  Google Scholar 

Oya A. Japanese Encephalitis Vaccine. Acta Paediatr Jpn. 1988;30:175–84.

CAS  Article  Google Scholar 

Kitaoka M. Host reactions following vaccination against Japanese encephalitis with special reference to neurological complications. In: Hammon WMD, Kitaoka M, Downs WG, editors. Immunization for Japanese encephalitis. Tokyo: Igaku Shoin Ltd; 1971. p. 275–7.

Google Scholar 

Okinaka T, Toyokura Y, Hea T. Physical reactions following vaccination against Japanese encephalitis with special reference to neurological complications. Adv Neurol Sci. 1967;42:206–20.

Google Scholar 

CDC. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 1993;42((no. RR-1)).

Defraites RF, Gambel JM, Hoke CH, Sanchez JL, Withers BG, Karabatsos N, et al. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg. 1999;61(2):288–93. https://doi.org/10.4269/ajtmh.1999.61.288.

CAS  Article  PubMed  Google Scholar 

Wang S-Y, Cheng X-H, Li J-X, Li X-Y, Zhu F-C, Liu P. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: a systematic review and meta-analysis. Human Vaccines Immunother. 2015;11(6):1418–25. https://doi.org/10.1080/21645515.2015.1011996.

Article  Google Scholar 

Li X, Ma S-J, Liu X, Jiang L-N, Zhou J-H, Xiong Y-Q, et al. Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Human Vaccines Immunother. 2014;10(12):3579–93. https://doi.org/10.4161/21645515.2014.980197.

Article  Google Scholar 

Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010;29(12):1111–7. https://doi.org/10.1097/INF.0b013e3181f68e9c.

Article  PubMed  Google Scholar 

Torresi J, McCarthy K, Feroldi E, Méric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine. 2010;28(50):7993–8000. https://doi.org/10.1016/j.vaccine.2010.09.035.

CAS  Article  PubMed  Google Scholar 

Xin YY, Ming ZG, Peng GY, Jian A, Min LH. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg. 1988;39(2):214–7. https://doi.org/10.4269/ajtmh.1988.39.214.

CAS  Article  PubMed  Google Scholar 

•• Ginsburg AS, Meghani A, Halstead SB, Yaich M. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: a review of safety and tolerability studies, Human Vaccines & Immunotherapeutics. 2017;13(10):2222–31. https://doi.org/10.1080/21645515.2017.1356496 -An excellent meta analysis review of the performance of SA14–14-2 live attenuated vaccine.

WHO. World Health Organization. Newly accessible Japanese encephalitis vaccine will make saving children easier in developing countries. Media Centre j WHO. 2013. [accessed 2016 Jun 11]. http://www.who.int/mediacentre/news/releases/2013/japanese_encephalitis_20131009/en/. 2013.

Kim DS, Houillon G, Jang GC, Cha S-H, Choi S-H, Lee J, et al. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. Human Vaccines Immunother. 2014;10(9):2656–63. https://doi.org/10.4161/hv.29743.

Article  Google Scholar 

Sanchayan K, Fernandopulle R, Amarasinghe A, Thiyahiny SN, Sri RS. Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka. Ceylon Med J. 2016;61(3):99–105. https://doi.org/10.4038/cmj.v61i3.8344.

CAS  Article  PubMed  Google Scholar 

Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine. 2005;23(45):5205–11. https://doi.org/10.1016/j.vaccine.2005.07.002.

Article  PubMed  Google Scholar 

Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine. 2000;18:26–32. https://doi.org/10.1016/S0264-410X(00)00038-4.

CAS  Article  PubMed  Google Scholar 

Kwon HJ, Lee SY, Kim KH, Kim DS, Cha SH, Jo DS, et al. The immunogenicity and safety of the live-attenuated SA 14-14-2 Japanese encephalitis vaccine given with a two-dose primary schedule in children. J Korean Med Sci. 2015;30(5):612–6.

Article  Google Scholar 

Turtle L, Tatullo F, Bali T, Ravi V, Soni M, Chan S, et al. Cellular immune responses to live attenuated Japanese encephalitis (JE) vaccine SA14-14-2 in adults in a JE/dengue co-endemic area. PLoS Negl Trop Dis. 2017;11(1):e0005263. https://doi.org/10.1371/journal.pntd.0005263.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Hsu TC, Chow LP, Wei HY. A completed field trial for an evaluation of the effectiveness of mouse-brain Japanese encephalitis vaccine. In: McD HW, Kitaoka M, Downs WG, editors. Immunization for Japanese encephalitis. Tokyo: Igaku Shoin Ltd; 1971. p. 258–65.

Google Scholar 

Kitano T, Yabe S, Kobayashi M. Immunogenicity of JE Nakayama and Beijing-1 vaccines. JE and HFRS Bull. 1986;1:37–41.

Google Scholar 

Yang S-E, Pan M-J, Tseng H-F, Liau M-Y. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine—results from 30 years experience in Taiwan. Vaccine. 2006;24(14):2669–73. https://doi.org/10.1016/j.vaccine.2005.10.054.

CAS  Article  PubMed  Google Scholar 

Gowal D, Tahlan AK. Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian J Med Res. 1995;102:267–71.

CAS  PubMed  Google Scholar 

Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51. Vaccine. 2011;29(14):2607–12. https://doi.org/10.1016/j.vaccine.2011.01.058.

CAS  Article  PubMed  Google Scholar